Navelbine [vinorelbine] Taxol [paclitaxel] Herceptin [trastuzumab] and Neuopogen [filgrastim] in stage IV breast cancer: A phase I-II trial
Latest Information Update: 17 Jul 2023
At a glance
- Drugs Filgrastim (Primary) ; Paclitaxel (Primary) ; Trastuzumab (Primary) ; Vinorelbine (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- 08 May 2017 Status changed from completed to discontinued.
- 01 Aug 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 28 Feb 2008 Planned end date changed from 1 Mar 2008 to 1 Aug 2008 as reported by ClinicalTrials.gov.